Atopic dermatitis (AD)
Conditions
Brief summary
1. Percent change from Baseline in EASI score at Week 12
Detailed description
1. Response of achieving 75% reduction in EASI (EASI75) score at Wk 12, 2. Response of achieving vIGA score of 0 or 1 with reduction from Baseline of ≥2 points at Wk 12, 3. Response of achieving ≥4-point decrease in PP-NRS score at Wk 12, 4. Change from baseline and percent change in: EASI score, affected BSA and PP-NRS score at each post-baseline visit, 5. Change from baseline and percent change in DLQI score and in POEM score at Wk 12, 6. Incidence, nature, and severity of treatment-emergent adverse events of soquelitinib compared with placebo
Interventions
DRUGPlacebo tablets
DRUGSoquelitinib
Sponsors
Corvus Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Percent change from Baseline in EASI score at Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Response of achieving 75% reduction in EASI (EASI75) score at Wk 12, 2. Response of achieving vIGA score of 0 or 1 with reduction from Baseline of ≥2 points at Wk 12, 3. Response of achieving ≥4-point decrease in PP-NRS score at Wk 12, 4. Change from baseline and percent change in: EASI score, affected BSA and PP-NRS score at each post-baseline visit, 5. Change from baseline and percent change in DLQI score and in POEM score at Wk 12, 6. Incidence, nature, and severity of treatment-emergent adverse events of soquelitinib compared with placebo | — |
Outcome results
None listed